Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018

	Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Source: Ablynx (Euronext Brussels and Nasdaq: ABLX)
Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018 Prospectus approved by the FSMA on March 27, 2018 and to be published on April 3, 2018 The initial acceptance period will commence on April 4, 2018 and expire on May 4, 2018, subject to extension Paris, France and Ghent, Belgium - March 29, 2018 - Sanofi and Ablynx announced today that on April 4, 2018, Sanofi will commence the previously announced tender offers to acquire all of the outstanding shares (including shares represented by American Depositary Shares ("ADS")), warrants and convertible bonds of Ablynx for: EUR 45.00 per share or ADS EUR 18.66 - EUR 41.79 per warrant[1] EUR 393,700.78 per convertible bond[2]   The tender offers, which are being made pursuant to the Heads of Agreement, dated January 28, 2018 between Sanofi and Ablynx, will be comprised of two separate but concurrent tender offers: (i) a tender offer under the laws of Belgium for all of the outstanding shares, warrants and convertible bonds of Ablynx (the "Belgian Offer") and (ii) a tender offer under the laws of the U.S. for all of the outstanding shares held by U.S. holders and ADSs held by holders, wherever located (the "U.S. Offer").   With Ablynx's innovative Nanobody® technology platform, Sanofi will continue to advance the strategic transformation of its Research and Development strategy, expanding its late-stage pipeline and strengthening its platform for growth in rare blood disorders. This acquisition builds on a successful existing partnership between Ablynx and Sanofi to develop and commercialize Nanobody-based therapeutics for the treatment of various immune-related inflammatory diseases.